Literature DB >> 33922473

Allosteric Modulation of the CB1 Cannabinoid Receptor by Cannabidiol-A Molecular Modeling Study of the N-Terminal Domain and the Allosteric-Orthosteric Coupling.

Jakub Jakowiecki1, Renata Abel2,3, Urszula Orzeł1, Paweł Pasznik1, Robert Preissner2, Sławomir Filipek1.   

Abstract

The CB1 cannabinoid receptor (CB1R) contains one of the longest N termini among class A G protein-coupled receptors. Mutagenesis studies suggest that the allosteric binding site of cannabidiol (CBD) involves residues from the N terminal domain. In order to study the allosteric binding of CBD to CB1R we modeled the whole N-terminus of this receptor using the replica exchange molecular dynamics with solute tempering (REST2) approach. Then, the obtained structures of CB1R with the N terminus were used for ligand docking. A natural cannabinoid receptor agonist, Δ9-THC, was docked to the orthosteric site and a negative allosteric modulator, CBD, to the allosteric site positioned between extracellular ends of helices TM1 and TM2. The molecular dynamics simulations were then performed for CB1R with ligands: (i) CBD together with THC, and (ii) THC-only. Analyses of the differences in the residue-residue interaction patterns between those two cases allowed us to elucidate the allosteric network responsible for the modulation of the CB1R by CBD. In addition, we identified the changes in the orthosteric binding mode of Δ9-THC, as well as the changes in its binding energy, caused by the CBD allosteric binding. We have also found that the presence of a complete N-terminal domain is essential for a stable binding of CBD in the allosteric site of CB1R as well as for the allosteric-orthosteric coupling mechanism.

Entities:  

Keywords:  CB1; CBD; GPCRs; REST2; THC; allosteric modulation; cannabinoid receptor; interaction fingerprints; molecular dynamics

Year:  2021        PMID: 33922473     DOI: 10.3390/molecules26092456

Source DB:  PubMed          Journal:  Molecules        ISSN: 1420-3049            Impact factor:   4.411


  43 in total

1.  The membrane proximal region of the cannabinoid receptor CB1 N-terminus can allosterically modulate ligand affinity.

Authors:  Jonathan F Fay; David L Farrens
Journal:  Biochemistry       Date:  2013-11-08       Impact factor: 3.162

Review 2.  Novel Allosteric Modulators of G Protein-coupled Receptors.

Authors:  Patrick R Gentry; Patrick M Sexton; Arthur Christopoulos
Journal:  J Biol Chem       Date:  2015-06-22       Impact factor: 5.157

3.  Scalable molecular dynamics on CPU and GPU architectures with NAMD.

Authors:  James C Phillips; David J Hardy; Julio D C Maia; John E Stone; João V Ribeiro; Rafael C Bernardi; Ronak Buch; Giacomo Fiorin; Jérôme Hénin; Wei Jiang; Ryan McGreevy; Marcelo C R Melo; Brian K Radak; Robert D Skeel; Abhishek Singharoy; Yi Wang; Benoît Roux; Aleksei Aksimentiev; Zaida Luthey-Schulten; Laxmikant V Kalé; Klaus Schulten; Christophe Chipot; Emad Tajkhorshid
Journal:  J Chem Phys       Date:  2020-07-28       Impact factor: 3.488

4.  In silico mapping of allosteric ligand binding sites in type-1 cannabinoid receptor.

Authors:  Annalaura Sabatucci; Daniel Tortolani; Enrico Dainese; Mauro Maccarrone
Journal:  Biotechnol Appl Biochem       Date:  2018-01-03       Impact factor: 2.431

5.  Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor.

Authors:  R B Laprairie; A M Bagher; M E M Kelly; E M Denovan-Wright
Journal:  Br J Pharmacol       Date:  2015-10-13       Impact factor: 8.739

6.  High-resolution crystal structure of the human CB1 cannabinoid receptor.

Authors:  Zhenhua Shao; Jie Yin; Karen Chapman; Magdalena Grzemska; Lindsay Clark; Junmei Wang; Daniel M Rosenbaum
Journal:  Nature       Date:  2016-11-16       Impact factor: 49.962

7.  Cannabidiol binding and negative allosteric modulation at the cannabinoid type 1 receptor in the presence of delta-9-tetrahydrocannabinol: An In Silico study.

Authors:  Hery Chung; Angélica Fierro; C David Pessoa-Mahana
Journal:  PLoS One       Date:  2019-07-23       Impact factor: 3.240

8.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.

Authors:  Chaolin Huang; Yeming Wang; Xingwang Li; Lili Ren; Jianping Zhao; Yi Hu; Li Zhang; Guohui Fan; Jiuyang Xu; Xiaoying Gu; Zhenshun Cheng; Ting Yu; Jiaan Xia; Yuan Wei; Wenjuan Wu; Xuelei Xie; Wen Yin; Hui Li; Min Liu; Yan Xiao; Hong Gao; Li Guo; Jungang Xie; Guangfa Wang; Rongmeng Jiang; Zhancheng Gao; Qi Jin; Jianwei Wang; Bin Cao
Journal:  Lancet       Date:  2020-01-24       Impact factor: 79.321

9.  SARS-CoV2 induced respiratory distress: Can cannabinoids be added to anti-viral therapies to reduce lung inflammation?

Authors:  Siddappa N Byrareddy; Mahesh Mohan
Journal:  Brain Behav Immun       Date:  2020-04-28       Impact factor: 7.217

10.  The potential of cannabidiol in the COVID-19 pandemic.

Authors:  Giuseppe Esposito; Marcella Pesce; Luisa Seguella; Walter Sanseverino; Jie Lu; Chiara Corpetti; Giovanni Sarnelli
Journal:  Br J Pharmacol       Date:  2020-07-16       Impact factor: 8.739

View more
  1 in total

Review 1.  Impact of Cannabinoid Compounds on Skin Cancer.

Authors:  Robert Ramer; Franziska Wendt; Felix Wittig; Mirijam Schäfer; Lars Boeckmann; Steffen Emmert; Burkhard Hinz
Journal:  Cancers (Basel)       Date:  2022-03-31       Impact factor: 6.639

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.